BIOCON - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 2.4
| Stock Code | BIOCON | Market Cap | 58,466 Cr. | Current Price | 361 ₹ | High / Low | 425 ₹ |
| Stock P/E | 300 | Book Value | 120 ₹ | Dividend Yield | 0.14 % | ROCE | 2.09 % |
| ROE | 0.40 % | Face Value | 5.00 ₹ | DMA 50 | 366 ₹ | DMA 200 | 369 ₹ |
| Chg in FII Hold | 0.13 % | Chg in DII Hold | 2.34 % | PAT Qtr | 111 Cr. | PAT Prev Qtr | 70.9 Cr. |
| RSI | 49.5 | MACD | -2.14 | Volume | 26,80,341 | Avg Vol 1Wk | 26,50,032 |
| Low price | 318 ₹ | High price | 425 ₹ | PEG Ratio | -16.1 | Debt to equity | 0.16 |
| 52w Index | 39.9 % | Qtr Profit Var | 3,183 % | EPS | 0.07 ₹ | Industry PE | 30.2 |
Biocon (BIOCON) shows weak fundamentals for swing trading. The stock is currently priced at ₹361, slightly below its 50 DMA (₹366) and 200 DMA (₹369), indicating lack of momentum. The very high P/E ratio (300 vs. industry average of 30.2), low ROCE (2.09%), and ROE (0.40%) highlight poor efficiency. Technical indicators (RSI ~49.5, MACD negative) suggest indecision. Despite strong quarterly profit growth, EPS remains extremely low (₹0.07), raising sustainability concerns.
🔑 Optimal Entry Price: ₹330–340, near support levels around ₹318.
📈 Exit Strategy (if already holding): Consider exiting near ₹390–400 resistance zone, or if price fails to sustain above ₹350 with volume confirmation.
✅ Positive
- Quarterly PAT growth from ₹70.9 Cr. to ₹111 Cr. (3183% variation)
- Low debt-to-equity ratio (0.16)
- DII holdings increased (+2.34%), showing institutional confidence
⚠️ Limitation
- Extremely high P/E ratio (300 vs. industry 30.2)
- Weak ROCE (2.09%) and ROE (0.40%)
- EPS very low at ₹0.07
📉 Company Negative News
- Profitability remains weak despite revenue growth
- Stock underperforms compared to industry peers
📈 Company Positive News
- Strong quarterly profit surge
- Institutional investors increasing stake
🏭 Industry
- Industry P/E at 30.2, much lower than Biocon’s valuation
- Biopharma sector has long-term growth potential but faces regulatory and competitive challenges
🔮 Conclusion
Biocon is not an ideal swing trade candidate due to overvaluation and weak fundamentals. Traders may cautiously enter near ₹330–340 with a strict stop-loss below ₹318. Exit should be targeted near ₹390–400 if momentum builds. Risk remains high, so conservative strategies are recommended.